Royalty Report: Drugs, Cancer, Disease – Collection: 363524

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • cell therapy
  • Drug Discovery
  • Pharmaceuticals
  • Antibody
  • Drug delivery
  • Stem cells

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 363524

License Grant
The parties are collaborating to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Licensor’s proprietary platform. Licensee and Licensor agreed to engage in up to three different research programs, each covering a collaboration target. Licensee has sole responsibility for all development and commercialization activities (including regulatory filing and approval).
License Property
CAR-NK cells are known to be effective against hematological malignancies, and a growing number of preclinical findings indicate that they have activity against non-hematological neoplasms.
Field of Use
The collaboration and license agreement is to develop novel chimeric antigen receptor (CAR)-NK cell therapies targeting solid tumor-associated antigens.
Licensee is developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer.

IPSCIO Record ID: 362483

License Grant
Licensors, as applicable, grant to Licensee of Switzerland an exclusive, sub-licensable license, under the Licensor IP in the Territory in the Field,
–  to generate and test Chimeric Antigen Receptor T-Cell Products solely for the Development, Regulatory Approval and Commercialization of Products containing such Chimeric Antigen Receptor I-Cell Products;
–  to Develop and Commercialize Products in the Field in the Territory, provided that such Products are not Out-of-Scope Products; and
–  to Commercialize the Chimeric Antigen Receptor for Products.
License Property
Licensor has expertise in and owns or controls proprietary technology relating to genetically engineering cells to target and destroy cancer cells.

Product means any pharmaceutical product containing a Chimeric Antigen Receptor I-Cell Product developed by Licensor under a Research Program for which the JSC determines to file an IND or under a research program for which Licensee has exercised the Licensor Program Option, or, any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Licensee that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described above.

Allogcneic Cell Therapy means a genomically engineered patient-nonspecific T-cell expressing a Chimeric Antigen Receptor for delivery to a patient developed under the Allogeneic Cell Therapy Research Program satisfying the Allogeneic Cell Therapy Criteria.

Chimeric Antigen Receptor T-Cell Product means a T-Cell having a Chimeric Antigen Receptor, or, a T-cell under switch control having a Chimeric Antigen Receptor and any Activator Ligands or Exclusive Activator Ligands that are administered to control such T-cells irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such T-cell directed to a Target, or, an Allogeneic Cell Therapy, or, the Allogeneic Cell Therapy under switch control having a Chimeric Antigen Receptor directed to a Target and any Activator Ligands or Exclusive Activator Ligands that are administered to control such Allogeneic Cell Therapy irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such Allogeneic Cell Therapy, or, any component sold as a kit, such as a device, delivery system or therapy scheme for the above to modify such T-cell including one or more polypeptides or nucleic acids encoding a CAR.

Licensor Platform Technology means Licensors platform of research tools and technology necessary for Licensor to perform its tasks directed towards the design, identification, culturing, and/or production of genetically modified cells consistent with this Agreement, including without limitation the technology embodied in the Licensor Materials and the Licensor Patents, and specifically including without limitation the following of Licensors platform areas and capabilities
(I) UltraVcctor,
(2) LEAP,
(3) DNA and RNA MOD engineering,
(4) protein engineering,
(5) transcription control chemistry,
(6) genome engineering,
(7) cell system engineering,
(8) Endometrial Regenerative Cells,
(9) the RheoSwitchE technology and RheoSwitch Therapeutic Systems, and
(10) MD Anderson CC Technologies.

Field of Use
The Field means the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans.

IPSCIO Record ID: 262605

License Grant
The Licensor, a not-for-profit corporation formed to hold, manage, and facilitate commercialization of the university's intellectual property, grants the French Licensee a royalty-bearing exclusive license under Patent Rights to use, develop, manufacture, market, and commercialize the Licensed Subject Matter in the field of Cancer Immunotherapy, including right to use the Patent 2014/036684 – CSI-Specific chimeric Antigen Receptor Engineered Immune Cells and Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cells for Cancer Immunotherapy.
License Property
Licensed Subject Matter is Cancer Immumotherapy, including US Patent United States Patent 10,227,409 granted March 12, 2019.
Field of Use
The Licensee is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.

IPSCIO Record ID: 308262

License Grant
Licensors, a University and a childrens research hospital, granted the Licensee, a related party, an exclusive, royalty-bearing, worldwide license to its patent rights related to a method for expanding natural killer cells; a chimeric receptor with NKG2D specificity; and a method for supporting autonomous natural killer cell function. The License Agreement provides the Licensee with the rights to grant and authorize sublicenses to make, have made, use, sell, offer for sale and import products and otherwise exploit the patent rights.
License Property
The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. We have engineered NKX101 to increase the cancer cell killing ability of our engineered NK cells by raising levels of NKG2D at least ten-fold as compared to non-engineered NK cells and by adding a costimulatory domain, which is an additional signaling element for white blood cells.

The two co-lead product candidates are NKX101 and NKX019. NKX101 is designed to enhance the power of innate NK biology to detect and kill cancerous cells

Field of Use
This agreement pertains to the drug industry relating to cell therapies to treat cancer with a method for expanding natural killer cells; a chimeric receptor and a method for supporting autonomous natural killer cell function.

IPSCIO Record ID: 372431

License Grant
The Parties, and others, entered into a settlement agreement to resolve litigation. Licensor became a party to the litigation after it entered into a license agreement with St. Jude Childrens Research Hospital, also a party in the litigation, for patent rights owned by St. Jude.

By this agreement, Licensee is obtaining a non-exclusive license to the Licensed Patents for use in the Field.

Licensor grants a non-exclusive sub license under the Licensed Patents for the Term of this Agreement to develop, have developed, make, have made, use, have used, import, offer for sale, have offered for sale, sell and have sold Licensed Products and Licensed Services.

License Property
Licensor is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer.

CART-19 shall mean a chimeric antigen receptor T cell directed against CD-19.

Penn Construct shall mean a CART-19 that includes a 4-1 BB signaling domain and a CD3s signaling domain.

Patent No. 8,399,645, titled 'Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.'

Field of Use
Patent coves the technology for chimeric antigen receptors (CARs) used in cancer immunotherapies.

IPSCIO Record ID: 346459

License Grant
For the Sublicense to Licensed Patents, Licensor grants a non-exclusive sublicense under the Licensed Patents for the Term of this Agreement to develop, have developed, make, have made, use, have used, import, offer for sale, have offered for sale, sell and have sold Licensed Products and Licensed Services, in each case, in the Field in the Territory.
License Property
CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.

Licensed Patents shall mean Chimeric receptors with 4-1BB stimulatory signaling domain, and, shall specifically exclude 7,435,596 and 8,026,097 , and any other patent or patent application that claims priority to, or common priority with, or is a divisional, continuation, re-issue, renewal, reexamination, substitution or extension of any patent or patent application identified in clause (a) above that contains only claims directed to the expansion of natural killer NK cells.

Licensed Product shall mean any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under this Agreement. For the avoidance of doubt, as of the Effective Date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, as defined under this Agreement.

Penn Construct shall mean a CART- 19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.

Licensor is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.

Field of Use
Patents cover the technology for chimeric antigen receptors (CARs) used in cancer immunotherapies.

IPSCIO Record ID: 307594

License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.

The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.

Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.

Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.

Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.

IPSCIO Record ID: 136308

License Grant
The University hereby grants to the Licensee an Exclusive license under the Licensed Patent in the Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Territory.
License Property
Trispecific Killer Engager (TriKE) technology developed by the Licensor to target NK cells to cancer.

U.S. Patent Application USSN 62/237,835 – Therapeutic compounds and its uses

Patent relates to commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.

Field of Use
The Licensee will further develop and commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology.

IPSCIO Record ID: 356954

License Grant
For the Development and Commercialization License, Licensor grants an exclusive license sublicenseable, under the Licensor Technology to research, make, have made and use Compounds in the Territory pursuant to the Next Gen Research Plan; to make or have made Licensed Compounds in the Territory for use in the manufacture of Licensed Products to develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Field in the Territory; and, an exclusive license, sublicenseable, under the Licensor know-how to research Subsequent Compounds in the Territory, to make or have made Subsequent Compounds in the Territory for research use or for use in the manufacture of Subsequent Products and to develop, make, have made, use, sell, offer for sale, and import, Subsequent Products in the Field in the Territory; and,
an exclusive license, sublicenseable, under the Licensor know-how, solely after the end of the Restriction Period, to research, develop, make, have made, use, sell, offer for sale, and import Compounds in the Field in the Territory.

For the Research License, Licensor grants a perpetual, irrevocable, non-exclusive, non-sublicensable except to Third Party contractors and service providers performing for the benefit of Licensee,  license under the Licensor Technology and Licensee Technology to make, import, and use but not to sell or offer for sale Compounds for internal research purposes only.

Licensor grants an option to obtain an exclusive, sublicense from Licensor to certain Patent Rights licensed to Licensor under the Georgia Regents Research Institute License Agreement or Lankcnau Institute for Medical Research License Agreements, to research, develop, make, have made, use, sell, offer for sale and import Compounds and Licensed Products in the Field in certain countries in the Territory.

License Property
Licensor controls certain patents and know-how relating to its proprietary program regarding inhibitors of the IDO Target and TDO Target, including patents and know-hem covering the lead compound NLG919 and other compounds that are inhibitors of one or both targets.  IDO Target means indoleamine 2,3-dioxygenase 1.  TDO Target means tryptophan 2,3-dioxygenase.

Licensed Compound means NLG919 or any Next Generation Compound.

NLG919 means Licensor’s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, as further described in IND 119045 or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Compound means a compound with a molecular weight of two thousand (2,000) Daltons or less], that hinds to and inhibits the activity of one or both of the 100 Target and TDO Target. with an IC50 of 1 µMor less in the applicable Enzymatic Assay, and that is being researched, developed or commercialized to exert its influence through the inhibition of one or both of the IDO Target or TDO Target, including NLG919, but excluding Indoximod.

Enzymatic Assay means, with respect to the IDO Target, the assay described in IND 119045 Document PD0l-MRMP01 1-SP04-E248, and, with respect to the TDO Target. Enzymatic Assay shall also include an alternate means of detecting the products of the enzyme reactions or minor changes in the above enzyme assay protocols, as agreed upon by the JRC. Any IC50s of control compounds measured with an alternate assay format should fall within 3-fold of the assay method.

Indoximod means Licensor’s proprietary small molecule IDO pathway inhibitor known as of the Execution Date as indoximod, or 1-methyl-D-tryptophan, or any, enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Field of Use
The agreement also calls for the Parties to engage in a research collaboration for the discovery of next generation IDO/TDO compounds, which represent potential breakthrough approaches to cancer therapy.

IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4, PD-1, and PD-L1 that represent potential breakthrough approaches to cancer therapy. The IDO pathway regulates immune response by suppressing T-cell activation which enables local tumor immune escape. Recent studies have demonstrated that the IDO pathway is active in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor draining lymph nodes whereby this pathway promotes peripheral tolerance to tumor associated antigens (TAAs). When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system. NewLink has a number of active programs directed at synthesizing inhibitors to the IDO pathway and additionally has discovered novel tryptophan-2,3-dioxygenase (TDO) specific inhibitors that are potential anti-cancer compounds which could function individually or in combination with IDO inhibition.

Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.

IPSCIO Record ID: 296898

License Grant
Licensor (a related party) grants to the Company an exclusive license to all Licensor IP relating to Advance Chemeric Antigen Vectors for Targeting Tumors for the development and/or commercialization of certain licensed products.
License Property
The parties co-develop a novel CART and CAR-NK platform for the treatment of solid tumors.  The development is at a pre-clinical stage.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 344529

License Grant
By the original agreement, Licensor, a not-for-profit pediatric treatment and research facility, grants an exclusive license to develop, make, have made, use, import, offer for sale, sell, and have sold the Licensed Products and Licensed Services worldwide under the Patent Rights in the Licensed Field.
License Property
The licensed property is the invention(s) titled Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.

This amendment #2 adds that Licensed Products shall mean, when used in relation to A Third Party Agreement, any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under the Third Party Sublicense Agreement. For the avoidance of doubt, as of the Third Party Sublicense Agreement. effective date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, and,

Adds that Licensed Services shall mean, when used in relation to the Third Party Sublicense Agreement, any service using a Licensed Product.

Penn Construct shall mean a CART-19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.  CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.

Patent Rights are amended to read Patent Rights, when used in relation to the Third Party Sublicense Agreement, shall mean the patent and patent applications listed in the Third Party Sublicense Agreement;  and specifically exclude 7,435,596 and 8,026,097.

Field of Use
The shall mean all therapeutic, diagnostic, preventative and palliative uses.

Licensee is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Chimeric antigen receptor (CAR) recognize and kill cancer cells.

IPSCIO Record ID: 65323

License Grant
The Company has a license agreement with the University under which the Company received an exclusive, worldwide license to develop and commercialize CNDO-109 to active NK cells for the treatment of cancer-related and other conditions.   Under the terms of the license agreement, the Company is allowed to grant sublicenses to third parties without the prior approval of the University.
License Property
The product candidate is CNDO-109, a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL).  The manufacturing process for CNDO-109 activated NK cells is currently under development.   The Company has produced a master cell bank and a working cell bank of CTV-1 cells in collaboration with Party A, and has contracted with Party B and C for services related to development, manufacture and testing services.  The Company is sponsoring an ongoing Phase 1/2 study in patients with AML who are in their first complete remission (CR1) and who are at a high risk of relapsing. This study has completed enrollment and is expected to remain open to follow the status of patients until mid-2016.  

With respect to CNDO-109, the Company has exclusive rights to International Patent Application No. PCT/GB2006/000960 and all pending United States and foreign counterpart applications including granted U.S. Patents No. 8,257,970 and 8,637,308 and the corresponding national phase applications granted in Australia and India and filed in Canada, Europe and Japan, directed to the stimulation of NK cells and related CNDO-109 compositions and methods including methods for the treatment of cancer and other conditions. This patent family has been in-licensed on an exclusive basis from University. The CNDO-109 patent has an expiration date of January 2029 in the absence of any patent term extension. By way of an amendment to the license agreement with Unversity, we also have exclusive rights to International Application No. PCT/GB2010/051135 and all pending United States and foreign counterpart applications including pending United States Patent Application Serial No. 12/833,694 and the corresponding national phase applications filed in Europe, Brazil, China, Israel, Singapore and South Africa, directed to the preservation of activated NK cells and related compositions and methods. The CNDO-109 patents that may issue from the former patent family would expire in July 2030 in the absence of any patent term extension. The amendment includes rights to certain additional confidential technologies as well.

CNDO-109 is a compound that has been shown to activate NK cells. When activated, NK cells have the ability to differentiate between normal cells and cancer cells, and kill cancer cells by granzyme mediated lysis, a biochemical process whereby the NK cells directly kill cancer cells by destroying their cell membranes and structures.

Field of Use
This agreement pertains to the drug industry relating to the treatment of cancer-related and other conditions.

IPSCIO Record ID: 318779

License Grant
In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Option Agreements were terminated and a royalty payment from the sale of IRX-2 was agreed upon to the Collaborator for a period of time.
License Property
IRX-2 is a novel cytokine-based therapy. IRX-2 active constituents, namely Interleukin-2 (IL-2) and other key cytokines are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. IRX-2 is naturally derived from human blood cells.

IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.
IRX-2 is produced under current good manufacturing practices, or cGMP, following stimulation of a specific population of human peripheral blood mononuclear cells (PMBC) using a specified mitogen. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes. Cytokine production induced by the employed mitogen mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. PBMCs are obtained from FDA-licensed blood banks meeting all criteria for further human use.

Field of Use
The field of use is for the treatment of cancer relating to advanced head and neck squamous cell cancer.

The Licensee is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer.

IPSCIO Record ID: 184504

License Grant
The amendment to the terms of the original collaboration agreement, among other things, converts the GITR and OX40 programs from profit-share to royalty-bearing programs.  In addition, the profit-share programs relating to two undisclosed targets were removed from the collaboration, with one reverting to Licensee and one to Licensor (the latter being the TIGIT antibody program).  The remaining three royalty-bearing programs in the collaboration targeting TIM-3, LAG-3 and one undisclosed target remain unchanged, and there are no more profit-share programs under the collaboration.

The original agreement entered into a broad, global alliance with the parties to discover, develop and commercialize novel immuno-therapeutics using the antibody platforms. The collaboration was initially focused on four CPM programs targeting GITR, OX40, TIM-3 and LAG-3, and in November 2015, was expanded by adding three novel undisclosed CPM targets.

License Property
The Licensor is a clinical-stage immuno-oncology (I-O) company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer.

GITR is an immune checkpoint agonist, one of a class of receptors that amplify the immune system’s response to cancer. GITR (glucocorticoid-induced TNFR-related protein) is a receptor expressed on select populations of T cells. Activation of GITR leads to a more powerful anti-tumor inflammatory response, increased production of inflammatory signaling molecules and increased resistance to immunosuppression.

OX40 (also known as CD134 and TNFRSF4), a member of the TNFR super-family, is an immune-response-enhancing receptor found on activated T cells. OX40 promotes proliferation of these activated T cells and prevents the immunosuppressive activity of inhibitory T cells. We believe that antibodies that activate OX40 may help increase immune system activity through both of these mechanisms. Furthermore, OX40 antibodies have the potential to work alone or in combination with other therapeutics. Combining with another agonist checkpoint antibody, which provides different, yet complementary signaling attributes may further augment anti-tumor responses.

Field of Use
Checkpoint antibodies effect the immune system, and are now being used in cancer treatment.

IPSCIO Record ID: 332563

License Grant
The Chinese Licensor and U.S. Licensee, by this collaboration is for the development and commercialization of toripalimab, Licensor’s anti-PD-1 antibody, in the United States and Canada. Upon satisfaction of closing conditions, The Parties will co-develop toripalimab, and Licensee will be responsible for all commercial activities in the licensed territory.

Under the terms of the agreement, Licensee will also be granted options to Licensor’s TIGIT-targeted antibody and next generation engineered IL-2 cytokine for evaluation as potential combination therapies with toripalimab, as well as certain negotiation rights to two early-stage checkpoint inhibitor antibodies.

JS006, an antibody targeting TIGIT.

JS018, a next-generation engineered IL-2 cytokine

Two additional undisclosed early-stage novel immuno-oncology drug candidates.

License Property
Toripalimab is a Chinese domestic anti-PD-1 monoclonal antibody, also approved for the second-line treatment of patients with unresectable or metastatic melanoma, and, supplemental NDAs of toripalimab for the third-line treatment of recurrent/ metastatic nasopharyngeal carcinoma and second-line treatment of metastatic urothelial carcinoma.

JS006 is an antibody targeting TIGIT, a clinically validated immune inhibitory checkpoint. Anti-TIGIT antibodies have demonstrated synergistic anti-tumor activity in combination with anti-PD-1 antibodies.

JS018 is a next-generation engineered IL-2 cytokine designed to inhibit stimulation of regulatory T cells while retaining stimulatory activity on effector T cells and natural killer (“NK”) cells. The option to JS018 is exercisable prior to initiation of Phase 2 clinical development.

Field of Use
This transaction expands Licensees late-stage pipeline into the rapidly growing checkpoint inhibitor market and in oncology with biosimilars.

By this Collaboration, the Parties plan to file additional toripalimab BLAs with the FDA over the next three years for multiple rare and highly prevalent cancers, including non-small cell lung cancer (“NSCLC”).

IPSCIO Record ID: 257238

License Grant
Licensor grants the German Licensee an exclusive, even as to Licensor, but not as to sublicensees of Licensee that receive a direct license from Licensor upon Licensees request, right and license, without the right to grant sublicenses, under Independent Licensor Technology, Licensor Collaboration Technology, Licensor Process Technology, and Licensors rights and interest in the Joint Collaboration Technology to use such manufacturing process to make and have made Approved Collaboration Products against a Non-Proprietary Target for sale and use in Europe.
License Property
Collaboration Product means any composition or formulation containing a BiTE Molecule binding to a Collaboration Target.

BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.

Target means a cell-surface antigen.  The list of proprietary targets is epha2, alpha – V, and, beta-3.

BiTE molecules are designed to direct the body’s cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.

Field of Use
This product collaboration is useful for the development of antibody-based pharmaceutical products.

Licensee's product candidates aim to efficiently redirect the patient’s immune response to tumor cells either through the use of specific recombinant antibodies for the eradication of cancer cells, as is the case with adecatumumab, or through BiTE molecules, which target cancer cells for elimination by the patient’s own T cells.

IPSCIO Record ID: 312594

License Grant
Licensors filed a complaint against Licensee in the U.S. District Court for the Central District of California. The complaint alleged that Yescarta* infringes certain claims of U.S. Patent No. 7,446,190 concerning CAR T cell technologies.

In April 2020, the Court granted in part Licensor’s motion and entered a final judgment awarding royalties on Licensee’s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.

License Property
CAR T refers to cell therapy.

Yescarta is a trademark of Licensee.   Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patient’s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.

Field of Use
Yescarta is cell therapy used in the treatment of cancer.  Licensee is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.

IPSCIO Record ID: 246212

License Grant
The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.
License Property
Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled  â€œIn vivo activation of natural killer cells'.

Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS

NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for antigen presentation, which is why they are called “natural killers.”

Field of Use
The term “Field” or “Field of Use” shall mean all applications of the Patent Rights.  Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.

Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 351110

License Grant
Licensor licensed to Licensee patents and materials for the development and commercialization of novel cancer immunotherapy agent derived from the VAC platform utilizing an antigen provided by Licensee.
License Property
VAC platform is an allogeneic, or “off-the-shelf,” cancer immunotherapy derived from pluripotent stem cells for which a clinical trial in non-small cell lung cancer.
Field of Use
The collaboration will generate a novel product candidate derived from Licensor’s investigational allogeneic VAC cancer immunotherapy platform and targeting a proprietary Tumor Associated Antigen (TAA) construct provided by Licensee, for the treatment of glioblastoma multiforme (GBM).

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke.

IPSCIO Record ID: 336300

License Grant
Licensor hereby grants to Licensee (a) an exclusive (even as to Licensor and its Affiliates), royalty bearing, sublicenseable (but only in accordance with Agreement (Sublicenses)), license under the Licensor Patents and its interest in the Collaboration Patents and (b) a non-exclusive, royalty bearing, sublicenseable (but only in accordance with Agreement  (Sublicenses)) license under the Licensor Licensed Know-How and its interest in the Collaboration Know-How, in each case, to Exploit Licensee Product(s) in the Licensed Field in the Territory during the Term.
License Property
Licensor Patents means the Patent Rights to the antibody nucleic acid sequences provided to Licensee under this Agreement, along with the polypeptide sequences encoded by said nucleic acid sequences, Derivatives of said polypeptide sequences, and nucleic acids encoding said Derivatives.

Licensee Product means (a) as it relates to a Licensee Target, other than an Additional Target, a CAR Product directed against such particular Licensee Target based upon or generated using the constructs or complexes for CAR Products generated in the conduct of the Preclinical Development Plan for such Licensee Target; and (b) as it relates to a Licensee Additional Target (if any) either a CAR Product or a TCR Product (but not both) directed against such Additional Target, based upon or generated using the constructs or complexes for CAR Products or TCR Products, as the case may be. generated in the conduct of the Preclinical Development Plan for such Additional Target.  For clarity, upon Licensor’s exercise of its option to obtain exclusive rights to an Licensor Optioned Target, Licensee Products shall exclude Licensor Optioned Products.

CAR Product means a pharmaceutical or biologic product containing an adoptive T cell expressing a CAR directed against a particular Target.

Licensee Target means a Target specified as a Licensee Target pursuant to this agreement  (Target Selection) or any New Target selected by Licensee.  For clarity, Licensee Target shall exclude any Removed Target.  Licensee Target excludes any Licensor Optioned Target.

Target means an antigen expressed on or in a tumor cell.

Field of Use
Field of use is for the development activities of certain cell-based therapy products. Licensed Field means any and all uses.

The Parties will jointly create preclinical development plans through IND filing with the FDA for the research and development of CAR-based product candidates that target certain antigens expressed on the cell surface of various cancers.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.